Zealand Pharma enters US partnership over pump system
Biotech company Zealand Pharma has gained access to an infusion pump from the US-based Deka, which will be used with the drug dasiglucagon for the treatment of severe low blood sugar. Zealand Pharma is also granted worldwide exclusive rights for the pump in combination with the drug.
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN
Zealand Pharma and Deka Research & Development have partnered up to developed an infusion pump system, which will include the drug dasiglucagon, meant to treat patients with congenital hyperinsulinism (CHI), which is severe and persistent low blood sugar, Zealand Pharma reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma sends obesity candidate to clinic
For subscribers
.jpg&w=384&q=75)
